IQV vs CRL stock comparison
Iqvia vs. Charles River Laboratories International · data as of November 13, 2026
Iqvia (IQV) has a market value of about $43.7B, Charles River Laboratories International (CRL) about $16.2B. Over their latest twelve months Iqvia had revenue of $17.3B and Charles River Laboratories International $4.0B.
On our five checks Iqvia scores higher: 1.6 out of 5 (weak) against 1.2 (weak).
By area, the stronger company is Iqvia on value; Charles River Laboratories International on future growth; Iqvia on track record; Charles River Laboratories International on financial health.
Iqvia is cheaper on earnings (P/E 32.3 vs. 367.4).
Iqvia leads on 17 of the compared lines and Charles River Laboratories International on 3.
Side by side
| IQV | CRL | |
|---|---|---|
| Size and price | ||
| Market cap | $43.7B | $16.2B |
| Share price | $265.12 | $337.97 |
| Score | ||
| Overall score (of 5) | 1.6 | 1.2 |
| Value | 1 | 0 |
| Future growth | 0 | 1 |
| Track record | 3 | 0 |
| Financial health | 1 | 2 |
| Shareholder returns | 3 | 3 |
| Valuation | ||
| P/E (TTM) | 32.3 | 367.4 |
| Forward P/E | 19.2 | 26.7 |
| Price / free cash flow | 21.0 | 40.5 |
| Price / sales | 2.5 | 4.1 |
| EV / EBITDA | 16.8 | 42.4 |
| PEG | 0.80 | — |
| DCF value vs. price | −24% | −76% |
| Business | ||
| Revenue | $17.3B | $4.0B |
| Net income | $1.4B | $40M |
| Free cash flow | $2.1B | $400M |
| Net margin | 8.1% | 1.0% |
| Gross margin (5-yr avg.) | — | — |
| ROIC (5-yr avg.) | 8.0% | 5.6% |
| Growth | ||
| Revenue growth (1 yr) | 5.9% | -0.9% |
| Revenue growth (5 yrs, per year) | 7.5% | 6.6% |
| EPS growth (5 yrs, per year) | 40.5% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$14.0B | -$2.7B |
| Dividend yield | None | None |
| Shareholder yield | 2.9% | 2.2% |
| Analysts | ||
| Upside to average target | +18% | +4% |
| Consensus rating | Strong buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: IQV TTM to September 30, 2026, CRL TTM to September 26, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Iqvia or Charles River Laboratories International?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Iqvia scores 1.6 out of 5 and Charles River Laboratories International 1.2; the table shows where each one is stronger.
Is Iqvia cheaper than Charles River Laboratories International?
On trailing earnings, Iqvia trades at a P/E of 32.3 and Charles River Laboratories International at 367.4, so Iqvia is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Iqvia or Charles River Laboratories International?
Over five years Iqvia grew revenue about 7.5% a year and Charles River Laboratories International about 6.6% a year.
Full Iqvia analysis → Full Charles River Laboratories International analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.